Open AccessThe efficacy and safety of Yuxingcao eye drops in the treatment of COVID-19 conjunctivitis
Author(s) -
Jiajun Wu,
Liqu Pu,
Hui Zhou,
Wenjia Qu,
Dandan Zhao,
Chunmeng Liu,
Xuewen Dong,
Fu-Wen Zhang
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000023093
Subject(s) - medicine , funnel plot , covid-19 , publication bias , pandemic , data extraction , medline , disease , intensive care medicine , meta analysis , infectious disease (medical specialty) , pathology , outbreak , political science , law
Background: Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). There is no specific cure for this disease, and the clinical management mainly depends on supportive treatment. This disease may affect SARS-CoV-2 conjunctivitis. Yuxingcao eye drops is used in treating COVID-19 conjunctivitis in China. Methods: A comprehensive literature search will be conducted. Two methodological trained researchers will read the title, abstract, and full texts and independently select the qualified literature according to inclusion and exclusion criteria. After assessment of the risk of bias and data extraction, we will conduct meta-analyses for outcomes related to COVID-19 conjunctivitis. The heterogeneity of data will be investigated by Cochrane X 2 and I 2 tests. Then publication bias assessment will be conducted by funnel plot analysis and Egger test. Results: The results of our research will be published in a peer-reviewed journal. Conclusion: Our study aims to systematically present the clinical evidence of Yuxingcao eye drops in treating COVID-19 conjunctivitis, which will be of significant meaning for further research and clinical practice. PROSPERO registration number: PROSPERO CRD42020209059.